CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized, Open-Label, Multicenter Phase III Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07879911
Title field or adapter rule: {'original_value': "A Randomized, Open-Label, Multicenter Phase III Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer", 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:30.585454+00:00
Published At: 2026-10-19T00:00:00+00:00
Record Updated At: 2026-10-19
Source Retrieved At: 2026-10-31T22:18:22.973355+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Triple Negative Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-19", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT07879911"
protocolSection.identificationModule.officialTitle: "A Randomized, Open-Label, Multicenter Phase III Study of SYS6043 Versus Investigator\u0027s Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

{'armGroupLabels': ['SYS6043'], 'description': 'Add details that will distinguish this intervention from other interventions in this or another clinical study.\n\nParticipants in the experimental group will receive SYS6043, administered on Day 1 of each cycle，Q3W.', 'name': 'Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ["Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin）"], 'description': 'Add details that will distinguish this intervention from other interventions in this or another clinical study.\n\nPaclitaxel (90 mg/m², intravenous, Days 1, 8, and 15 of each 4 week cycle \\[Q4W\\]; or 80 mg/m², intravenous, Days 1, 8, and 15 of each 3 week cycle \\[Q3W\\]); Nab paclitaxel (100 mg/m², intravenous, Days 1, 8, and 15, Q4W); Capecitabine (1000 1250 mg/m², orally, twice daily on Days 1 14, Q3W); Eribulin (1.4 mg/m², intravenous, Days 1 and 8, Q3W); Carboplatin (administered on Day 1 at an area under the curve \\[AUC\\] of 6, Q3W).', 'name': "Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin）", 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.